Welcome to Nexpep

Nexpep's principal aim is to develop a treatment designed to replace a gluten-free diet for coeliac disease sufferers. Our scientists are world leaders in coeliac disease research and have developed robust science and patents, and a drug approved for entry into human trials. more...

Nexvax2 – developed from ground breaking research

Nexpep has developed the peptide-based therapeutic vaccine, Nexvax2, based upon ground-breaking research. We have completed preclinical development, and have commenced clinical trials to test the effects of Nexvax2 in patients with coeliac disease. more…

Nexpep as a business prospect

With a global increase of approximately 20% per annum in the number of people diagnosed with coeliac disease, there is a growing market for a vaccine. The current therapy for coeliac disease is problematic and costly, with a 50% failure rate, and a cost of $1 billion based on the gluten-free food market. more...

Our news and Nexpep in the media

More news ....